RxDoctor Payments Data

Mark Head, MD

Internal Medicine · Jeffersonville, INNPI 1639172570

Payments from drug & device makers

$9,367in general payments, 2019–2025

Across 582 payments — averaging $16.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$1K
  • Pfizer$834
  • GSK$694
  • Novo Nordisk$681
  • Johnson & Johnson$479
  • plus $4K from 34 others

What the payments were for

  • Food & beverage$9,27299%
  • Education$951%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,367 in reported general payments places this provider in the 90th percentile of 1,747 internal medicine providers in Indiana.

See all internal medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$148,640
Medicare patients
283
Services billed
4,047

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin87$131,094
EliquisApixaban87$112,257
OzempicSemaglutide34$54,378
JanuviaSitagliptin Phosphate35$42,664
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$37,845
Tresiba Flextouch U-200Insulin Degludec12$27,022
MounjaroTirzepatide25$26,781
LinzessLinaclotide18$26,130
FarxigaDapagliflozin Propanediol21$23,079
XareltoRivaroxaban17$17,474
Combivent RespimatIpratropium/Albuterol Sulfate17$17,173
Repatha SureclickEvolocumab11$7,067
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen241$6,600
Lantus SolostarInsulin Glargine,hum.Rec.Anlog38$5,808
TrintellixVortioxetine Hydrobromide12$5,780

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Combivent Respimat$228$148,266104 claims
PfizerEliquis$834$112,25787 claims
Novo NordiskOzempic$681$54,37834 claims
GSKTrelegy Ellipta, Breo Ellipta$694$43,41838 claims
MerckJanuvia$166$42,66435 claims
AbbVieLinzess, Synthroid$1,488$27,91449 claims
Lilly USA, LLCMounjaro$386$26,78125 claims
AstraZenecaFarxiga$1,024$23,07921 claims
Johnson & JohnsonXarelto$479$17,47417 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$124$10,35624 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,747 internal medicine providers in Indiana.

Other internal medicine in Jeffersonville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →